Relay Therapeutics (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 972 Shares

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 972 shares of the stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $14.79, for a total transaction of $14,375.88. Following the completion of the transaction, the chief financial officer directly owned 212,895 shares of the company’s stock, valued at approximately $3,148,717.05. The trade was a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, April 7th, Thomas Catinazzo sold 17,717 shares of Relay Therapeutics stock. The stock was sold at an average price of $13.01, for a total transaction of $230,498.17.
• On Thursday, April 9th, Thomas Catinazzo sold 1,800 shares of Relay Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $27,000.00.

Relay Therapeutics Price Performance

RLAY stock opened at $12.96 on Friday. Relay Therapeutics, Inc. has a 1 year low of $2.67 and a 1 year high of $17.32. The company has a market cap of $2.48 billion, a P/E ratio of -8.00 and a beta of 1.57. The firm has a 50-day moving average of $11.87 and a 200 day moving average of $9.13.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.06. The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $4.34 million. On average, equities research analysts expect that Relay Therapeutics, Inc. will post -1.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Relay Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its holdings in shares of Relay Therapeutics by 591.7% during the fourth quarter. SG Americas Securities LLC now owns 220,949 shares of the company’s stock valued at $1,869,000 after buying an additional 189,004 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Relay Therapeutics during the third quarter valued at approximately $399,000. Commodore Capital LP grew its holdings in shares of Relay Therapeutics by 27.3% during the third quarter. Commodore Capital LP now owns 17,000,000 shares of the company’s stock valued at $88,740,000 after buying an additional 3,650,000 shares during the last quarter. Mayport LLC purchased a new stake in shares of Relay Therapeutics during the third quarter valued at approximately $259,000. Finally, HighVista Strategies LLC grew its holdings in shares of Relay Therapeutics by 60.6% during the third quarter. HighVista Strategies LLC now owns 240,459 shares of the company’s stock valued at $1,255,000 after buying an additional 90,758 shares during the last quarter. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on RLAY. The Goldman Sachs Group upped their price objective on shares of Relay Therapeutics from $13.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday. JonesTrading began coverage on shares of Relay Therapeutics in a report on Tuesday, April 14th. They issued a “hold” rating and a $18.00 price objective on the stock. HC Wainwright upped their price objective on shares of Relay Therapeutics from $19.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday. Citizens Jmp upped their price objective on shares of Relay Therapeutics from $17.00 to $19.00 and gave the stock a “market outperform” rating in a report on Tuesday. Finally, Oppenheimer upped their price objective on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.56.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.